Fermenta Biotech's Q4 FY 2025-26 Quarterly Results

Result Summary

• Fermenta Biotech Ltd reported a 9.8% quarter-on-quarter (QoQ) decrease in its consolidated revenues for the quarter-ended Mar (Q4 FY 2025-26). On a year-on-year (YoY) basis, it witnessed a decline of 11.9%.
• Its expenses for the quarter were down by 9.3% QoQ and 2.0% YoY.
• The net profit increased 54.7% QoQ and decreased 44.2% YoY.
• The earnings per share (EPS) of Fermenta Biotech Ltd stood at 6.61 during Q4 FY 2025-26.

Financial Statments for Q4 FY 2025-26

---

Data Source: BSE, Company announcements The securities quoted are exemplary and are not recommendatory. Past performance is not indicative of future results

Company Overview

Fermenta Biotech Ltd, a well-regarded entity in the biotechnology industry, primarily engages in the manufacture and distribution of enzyme-based products. The company has carved a niche for itself by focusing on producing Vitamin D3, which is used in pharmaceuticals, dietary supplements, and feed industries. Fermenta Biotech operates in a dynamic industry that is characterized by rapid technological advancements and regulatory changes. As of the most recent updates available, there have been no major developments or announcements about new product lines or strategic shifts in their business operations. The company continues to leverage its expertise in biotechnology to sustain its position in the market.

Revenue

In the fourth quarter of the fiscal year 2026, Fermenta Biotech Ltd reported a total income of ₹126.65 crores, which marks a decrease of 9.8% compared to the previous quarter's income of ₹140.48 crores. Year-over-year, the total income has declined by 11.9% from ₹143.74 crores reported in the fourth quarter of fiscal year 2025. These changes highlight a downward trend in the company's revenue generation over both the quarterly and annual periods. The decrease in income on both timeframes could reflect various market conditions or internal factors impacting the company's sales performance during these periods.

Profitability

For the quarter ending in FY26, Fermenta Biotech Ltd's profit before tax was ₹26.21 crores, showing a significant quarter-over-quarter increase of 49.9% from ₹17.48 crores in Q3FY26. However, there is an 18.0% year-over-year decrease from ₹31.98 crores in Q4FY25. The company's profit after tax also saw a notable quarter-over-quarter increase of 54.7%, rising from ₹12.02 crores to ₹18.60 crores. Despite this, the year-over-year profit after tax is down by 44.2% from ₹33.32 crores. The earnings per share (EPS) for Q4FY26 were ₹6.61, reflecting a 52.3% increase QoQ but a 43.9% decrease YoY from ₹11.79. The tax paid in the current quarter was ₹7.61 crores, representing a 39.4% increase QoQ, and a significant reversal from a tax rebate position a year ago. These figures indicate fluctuations in the company's profitability across different periods.

Operating Metrics

The total expenses for Fermenta Biotech Ltd in Q4FY26 were reported at ₹109.51 crores, which is a reduction of 9.3% from the previous quarter's expenses of ₹120.80 crores. Year-over-year, the expenses have decreased by 2.0% from ₹111.75 crores. This decrease in expenses, both quarterly and annually, suggests effective cost management or changes in operational dynamics. The company's ability to reduce expenses while managing its income and profitability highlights its operational strategies during the fiscal period. The shifts in these key operating metrics are crucial for understanding the company's financial health and operational efficiency over the reported periods.